A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Exagen Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 84,100 shares of XGN stock, worth $761,105. This represents 0.0% of its overall portfolio holdings.

Number of Shares
84,100
Holding current value
$761,105
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$6.78 - $10.92 $570,198 - $918,372
84,100 New
84,100 $918,000

Others Institutions Holding XGN

About EXAGEN INC.


  • Ticker XGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 16,260,400
  • Market Cap $147M
  • Description
  • Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...
More about XGN
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.